Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Edouard L Fu

Showing results (31-40 of 79) with videos related to

Pageof 8
Sort By:
European Heart Journal. Cardiovascular Pharmacotherapy|January 31, 2020
Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarctionMarco Trevisan, Edouard L Fu, Karolina Szummer, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 8, 2022
Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral AnticoagulantsMarco Trevisan, Paul Hjemdahl, Catherine M Clase, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 9, 2024
Hyperkalemia and maintenance of renin-angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitorsAlessandro Bosi, Yang Xu, Anne-Laure Faucon, et al.
International Journal of Cardiology|January 25, 2022
Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practiceEdouard L Fu, Catherine M Clase, Roemer J Janse, et al.
Journal of the American Society of Nephrology : JASN|December 29, 2020
Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide StudyEdouard L Fu, Marie Evans, Catherine M Clase, et al.
JAMA Internal Medicine|January 20, 2026
SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 DiabetesSimon K Jensen, Uffe Heide-Jørgensen, Ina T Andersen, et al.
European Heart Journal|March 26, 2021
Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney functionYpe de Jong, Edouard L Fu, Merel van Diepen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 8, 2025
Care Processes and Clinical Responses to Newly Detected Albuminuria: The Stockholm Creatinine Measurements (SCREAM) ProjectAntoine Créon, Anne-Laure Faucon, Aurora Caldinelli, et al.
Clinical Kidney Journal|June 6, 2022
Stopping versus continuing renin-angiotensin-system inhibitors after acute kidney injury and adverse clinical outcomes: an observational study from routine care dataRoemer J Janse, Edouard L Fu, Catherine M Clase, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 27, 2020
Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort StudyEdouard L Fu, Catherine M Clase, Marie Evans, et al.
Pageof 8

Showing results (31-40 of 79) with videos related to

Sort By:
Pageof 8
European Heart Journal. Cardiovascular Pharmacotherapy|January 31, 2020
Glucagon-like peptide-1 receptor agonists and the risk of cardiovascular events in diabetes patients surviving an acute myocardial infarctionMarco Trevisan, Edouard L Fu, Karolina Szummer, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|October 8, 2022
Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral AnticoagulantsMarco Trevisan, Paul Hjemdahl, Catherine M Clase, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|October 9, 2024
Hyperkalemia and maintenance of renin-angiotensin system inhibitor therapy after initiating SGLT-2 or DPP-4 inhibitorsAlessandro Bosi, Yang Xu, Anne-Laure Faucon, et al.
International Journal of Cardiology|January 25, 2022
Comparative effectiveness of SGLT2i versus GLP1-RA on cardiovascular outcomes in routine clinical practiceEdouard L Fu, Catherine M Clase, Roemer J Janse, et al.
Journal of the American Society of Nephrology : JASN|December 29, 2020
Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide StudyEdouard L Fu, Marie Evans, Catherine M Clase, et al.
JAMA Internal Medicine|January 20, 2026
SGLT2 Inhibitors vs GLP-1 Receptor Agonists for Kidney Outcomes in Individuals With Type 2 DiabetesSimon K Jensen, Uffe Heide-Jørgensen, Ina T Andersen, et al.
European Heart Journal|March 26, 2021
Validation of risk scores for ischaemic stroke in atrial fibrillation across the spectrum of kidney functionYpe de Jong, Edouard L Fu, Merel van Diepen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|December 8, 2025
Care Processes and Clinical Responses to Newly Detected Albuminuria: The Stockholm Creatinine Measurements (SCREAM) ProjectAntoine Créon, Anne-Laure Faucon, Aurora Caldinelli, et al.
Clinical Kidney Journal|June 6, 2022
Stopping versus continuing renin-angiotensin-system inhibitors after acute kidney injury and adverse clinical outcomes: an observational study from routine care dataRoemer J Janse, Edouard L Fu, Catherine M Clase, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|November 27, 2020
Comparative Effectiveness of Renin-Angiotensin System Inhibitors and Calcium Channel Blockers in Individuals With Advanced CKD: A Nationwide Observational Cohort StudyEdouard L Fu, Catherine M Clase, Marie Evans, et al.
Pageof 8